Earlier this month, TriHealth was the recipient of $18 million in grants from bi3 (the funding arm of Bethesda Inc., one of our two sponsors) to fund the start-up of our Precision Medicine, Behavioral Health, and Health Equities programs. Thanks to bi3’s $4.3 million start-up grant, TriHealth will launch the region's first formalized multi-disciplinary Precision Medicine Institute, giving tens of thousands of tristate patients access to customized, preventive and potentially lifesaving genetic care.

 

The goal of Precision Medicine is to tailor care to the individual patient using their unique genetic make-up. Increasingly, medical policies and societal guidelines recommend genetic testing as an essential clinical data element used to predict disease, assess risk, select therapy, prevent adverse drug reactions, and enroll patients in clinical trials.

 

The TriHealth Precision Medicine Institute will include staff genetic counseling experts in key clinical areas such as preventive health, cancer risk, precision oncology, heredity cardiology, women's services and pharmacogenomics.

 

In addition to expanding access to customized, preventive genetic care, the launch of the TriHealth Precision Medicine Institute will also enable TriHealth clinicians to:

At its core, Precision Medicine improves the quality of care and the quality of life for patients in very individualized ways. 

 

We are grateful for bi3’s support, which is helping TriHealth fully integrate Precision Medicine into our world-class care delivery model – all to ensure we continue to lead the way in getting healthcare right for every patient we serve.